Close
Smartlab Europe
Achema middle east

News

Odyssey Health Selects Syneos to Support Concussion Treatment Trial

Odyssey Health, Inc., a company focused on developing life-enhancing medical products, has selected Syneos Health, a biopharmaceutical services organization to support its Investigational New Drug (IND) Application. Odyssey Health is developing a pharmaceutical treatment for mild Traumatic Brain Injury...

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

Myricx Bio, a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development...

Chiesi, Haisco Partner on DPP1 Inhibitor for Respiratory Diseases

Chiesi Farmaceutici S.p.A, an international, research-focused biopharmaceuticals and healthcare group, and Haisco Pharmaceutical Group Co. Ltd entered a licensing agreement to develop, manufacture, and commercialize outside China and adjacent territories (Hong Kong SAR, Macau SAR, and Taiwan District) HSK31858,...

Cryoport’s CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express

Cryoport, Inc., a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences announced the expansion of its global supply chain...

The Role of Robotics in Urological Surgeries: Precision, Outcomes, and Training

The advancements in technology and the desire for minimally invasive surgeries have converged to propel the field of robotic urological surgeries to the forefront. As the healthcare landscape evolves, robotics' importance is becoming increasingly evident, particularly within the urological sphere....

Connected Devices Making Their Presence Felt In Pharma

The market when it comes to connected drug delivery devices is going through rapid growth, with an expected annual market growth rate of more than 20% between 2023 and 2030. This progress is driven, in part, by the increasing...

Reference Approval Agencies Expanded By NPRA In Malaysia

The National Pharmaceutical Regulatory Agency- NPRA of Malaysia has recently gone on to revise its guidelines with regards to the approval pathways for medicines that have already been authorized in certain overseas territories. The changes made by NPRA go on...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »